| Bioactivity | PF-05214030 is a TRPV4 antagonist (IC50: 4 and 27nM for hTRPV4 and rTRPV4 respectively). PF-05214030 reverses the reduction in bladder capacity caused by intravesical infusion of a TRPV4 agonist[1][2]. |
| CAS | 1669444-50-1 |
| Formula | C17H13Cl2FN2O4S |
| Molar Mass | 431.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiang Y, et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022 Mar 24;15(1):34. [2]. Sarah Skerratt, et al. The Discovery and Optimisation of a Highly Selective Series of TRPV4 Antagonists. |
PF-05214030
CAS: 1669444-50-1 F: C17H13Cl2FN2O4S W: 431.27
PF-05214030 is a TRPV4 antagonist (IC50: 4 and 27nM for hTRPV4 and rTRPV4 respectively). PF-05214030 reverses the reduct
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.